Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial

https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00313-9/abstract?utm_campaign=update-landia&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_landia&_hsenc=p2ANqtz--nZHHxrv7Oog78MYqs5Iu5Z_VH1ZoZH45fHUuJDpdzU-KJO615ZIzT8_r1dnDTOC35OvEw8gA0hPFIOQcgc3v19zJ8NQ&_hsmi=351234214&utm_content=351151133&utm_source=hs_email